Xarelto

Xarelto
Name	Xarelto

Xarelto is a medication developed by Bayer and Johnson & Johnson's Janssen Pharmaceuticals division, used to prevent blood clots in patients with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. It is an anticoagulant that works by inhibiting Factor Xa, a crucial enzyme in the coagulation cascade, similar to rivaroxaban and apixaban, which are also used to treat patients with cardiovascular disease at Cleveland Clinic and Mayo Clinic. Xarelto has been studied in several clinical trials, including the ROCKET AF trial, which compared its efficacy and safety to warfarin in patients with atrial fibrillation at Duke University and University of California, Los Angeles.

Introduction

Xarelto, also known as rivaroxaban, is a small molecule anticoagulant that has been approved by the US Food and Drug Administration (FDA) for several indications, including the prevention of stroke and systemic embolism in patients with atrial fibrillation not caused by heart valve problems at NewYork-Presbyterian Hospital and University of Pennsylvania Health System. It is also used to treat and prevent deep vein thrombosis and pulmonary embolism in patients at Massachusetts General Hospital and University of California, San Francisco. Xarelto has been compared to other anticoagulants, such as warfarin and aspirin, in several clinical trials, including the EINSTEIN trial and the COMPASS trial, which were conducted at University of Oxford and McMaster University.

Mechanism_of_Action

Xarelto works by inhibiting Factor Xa, a crucial enzyme in the coagulation cascade that is involved in the formation of blood clots at National Institutes of Health and European Medicines Agency. By inhibiting Factor Xa, Xarelto prevents the formation of thrombin, which is the final enzyme in the coagulation cascade that converts fibrinogen to fibrin, forming a blood clot at University of Cambridge and Karolinska Institutet. Xarelto has a high affinity for Factor Xa and inhibits it in a dose-dependent manner, similar to other anticoagulants such as apixaban and edoxaban, which are used to treat patients with cardiovascular disease at Columbia University and University of Chicago.

Medical_Uses

Xarelto is approved for several medical uses, including the prevention of stroke and systemic embolism in patients with atrial fibrillation not caused by heart valve problems at Brigham and Women's Hospital and Stanford University. It is also used to treat and prevent deep vein thrombosis and pulmonary embolism in patients at University of California, Los Angeles and Duke University. Additionally, Xarelto is used to prevent blood clots in patients undergoing knee replacement surgery or hip replacement surgery at Hospital for Special Surgery and Rothman Institute. Xarelto has been compared to other anticoagulants, such as warfarin and aspirin, in several clinical trials, including the ROCKET AF trial and the COMPASS trial, which were conducted at University of Oxford and McMaster University.

Side_Effects

Xarelto, like other anticoagulants, can cause several side effects, including bleeding and anemia at National Institutes of Health and European Medicines Agency. The most common side effects of Xarelto are bleeding and bruising, which can be serious and even life-threatening in some cases at Cleveland Clinic and Mayo Clinic. Xarelto can also cause allergic reactions, such as hives and itching, and can increase the risk of stroke and systemic embolism if it is stopped abruptly at University of California, San Francisco and Massachusetts General Hospital. Xarelto has been associated with several rare but serious side effects, including spinal hematoma and epidural hematoma, which can cause paralysis and death at Johns Hopkins University and University of Pennsylvania Health System.

History

Xarelto was first approved by the US Food and Drug Administration (FDA) in 2011 for the prevention of deep vein thrombosis and pulmonary embolism in patients undergoing knee replacement surgery or hip replacement surgery at Hospital for Special Surgery and Rothman Institute. Since then, it has been approved for several other indications, including the prevention of stroke and systemic embolism in patients with atrial fibrillation not caused by heart valve problems at NewYork-Presbyterian Hospital and University of Pennsylvania Health System. Xarelto has been studied in several clinical trials, including the ROCKET AF trial and the COMPASS trial, which were conducted at University of Oxford and McMaster University.

Pharmacology

Xarelto is a small molecule anticoagulant that is absorbed quickly and reaches peak plasma concentrations within 2-4 hours after oral administration at National Institutes of Health and European Medicines Agency. It has a half-life of approximately 5-9 hours and is eliminated primarily through the kidneys and liver at University of Cambridge and Karolinska Institutet. Xarelto is metabolized by several cytochrome P450 enzymes, including CYP3A4 and CYP2J2, and can interact with several other medications, including ketoconazole and ritonavir, which are used to treat patients with HIV/AIDS at University of California, Los Angeles and Duke University. Xarelto has been compared to other anticoagulants, such as warfarin and aspirin, in several clinical trials, including the EINSTEIN trial and the COMPASS trial, which were conducted at University of Oxford and McMaster University.

Category:Pharmacology